DOCSLIB.ORG

Update on Approved and Candidate COVID-19 Vaccines in the EU

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update on Approved and Candidate COVID-19 Vaccines in the EU Update on approved and candidate COVID-19 vaccines in the EU Dr. Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy, EMA An agency of the European Union Outline 1 EMA response to COVID-19 pandemic - milestones 2 COVID-19 vaccines approved in the EU 3 Benefits and risks of COVID-19 vaccines 4 Real world evidence on effectiveness 5 Studies in children 6 Vaccines under review by EMA 7 Adapting COVID-19 vaccines to variants 8 Additional information Classified as public by the European Medicines Agency EMA RESPONSE TO COVID-19 PANDEMIC Milestones in the fight against the pandemic Scientific & regulatory Rapid development & Transparency & mobilisation evaluation outreach Approval: Comirnaty, COVID-19 vaccine Moderna, COVID-19 vaccine AstraZeneca, COVID-19 vaccine Janssen Accelerated development & evaluation procedures WHO declares pandemic COVID-19 Experts’ Task Force Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 1 Classified as public by the European Medicines Agency COVID-19 vaccines approved in the EU 4 vaccines authorised in the EU • Comirnaty and Moderna vaccines contain a molecule called messenger RNA (mRNA) with instructions for producing the spike protein from SARS-CoV-2, the virus that causes COVID-19 • The AstraZeneca and Janssen vaccine uses a non-replicating adenovirus as a carrier that has been modified to produce the spike protein from SARS-CoV-2. • The vaccines do not contain the SARS-CoV-2 virus causing COVID-19 itself and cannot cause the disease. Comirnaty COVID-19 Vaccine COVID-19 Vaccine COVID-19 Vaccine (BioNTech/Pfizer) Moderna AstraZeneca Janssen 21 Dec 6 Jan 29 Jan 11 Mar 2 Classified as public by the European Medicines Agency BENEFITS AND RISKS Efficacy of COVID-19 vaccines in trials All COVID-19 vaccines approved in the EU have a positive benefit-risk balance in prevention of COVID-19 disease. • mRNA vaccines show very high efficacy in trials in preventing symptomatic COVID of any severity • Viral vectored vaccines also demonstrated protection against symptomatic COVID • Since vaccines have been studied in different trials, it not possible to make direct comparison of the efficacy rates reported • Data on prevention of severe disease, hospitalisation and death from clinical trials are limited but all showing a trend towards high level of protection • Currently there are limited information from clinical trials with respect to protection against emerging variants • Some Real World data with respect to prevention of infection have been reported but more data are needed for proper estimation 3 Classified as public by the European Medicines Agency BENEFITS AND RISKS Positive benefit risk for COVID-19 vaccines Good safety profile, comparable to vaccines for other diseases • Most common side effects are usually mild or moderate and temporary. • These include pain and tenderness at injection site, headache, tiredness, muscle pain, general feeling of being unwell, chills, fever, joint pain and nausea. • Very rare but severe allergic reactions have occurred in people receiving the vaccine (in less than 1 in 100,000 people) • Very rare events of severe thrombosis combined with thrombocytopenia after Astra Zeneca vaccination have occurred in around 1 in a million people, and are under investigation • Long term safety is being monitored. Full scientific details and product information: Comirnaty | COVID-19 Vaccine Moderna | COVID-19 Vaccine AstraZeneca | COVID-19 vaccine Janssen 3 Classified as public by the European Medicines Agency REAL WORLD EVIDENCE ON EFFECTIVENESS Data from the real world to complement clinical trial data • EMA plans to use Real World Evidence (RWE) from clinical practice to monitor the safety and effectiveness of COVID-19 vaccines • Real-world monitoring complements EMA's regular safety-monitoring activities • RWD can inform vaccination campaigns and changes in current practise • These studies will provide information: • on how long protection lasts • how well the vaccine prevents severe COVID-19 • how well it protects immunocompromised people and pregnant women • whether it prevents asymptomatic cases and blocks transmission 4 Classified as public by the European Medicines Agency REAL WORLD EVIDENCE ON EFFECTIVENESS Preliminary studies on COVID-19 vaccine effectiveness 4 effectiveness studies available from Israel and UK • Preliminary assessment by EMA’s COVID-19 Task Force - early data promising: • Comirnaty: prevention of infection in Israel (92% effectiveness after 2 doses) • Astra Zeneca and Comirnaty: Substantial reduction in risk of hospitalisation in UK (>80%), but more data awaited • Comirnaty: data confirm the efficacy from the clinical trials and the booster effect of the second dose • COVID-19 Vaccine Astra Zeneca: Initial data show high protection from COVID-19, including severe disease, after first dose • In addition, emerging data from large clinical trial pointing to high efficacy including in the elderly 4 Classified as public by the European Medicines Agency Studies in children • The vaccines are currently not approved for younger children: • Comirnaty can be given above 16 years of age • Moderna , Astra Zeneca and Janssen can be given above 18 years of age • Vaccines will be first tested in adolescents and then progressively in children below 12 years of age down to the youngest ages • It is not known at the moment when these data will be submitted because the studies are still ongoing. • The two authorised mRNA vaccines are recruiting adolescents at a fast pace into clinical studies 5 Classified as public by the European Medicines Agency COVID-19 VACCINES UNDER REVIEW BY EMA Novavax (NVX-CoV2373) • Start of rolling review: 03/02/2021 • Protein-based vaccine containing tiny particles made from a laboratory-grown version of the spike (S) protein found on the surface of SARS-CoV-2 coronavirus. • It also contains an adjuvant to help strengthen the immune responses to the vaccine 6 Classified as public by the European Medicines Agency COVID-19 VACCINES UNDER REVIEW BY EMA CureVac (CVnCoV vaccine) • Start of rolling review: 12/02/2021 • CVnCoV contains mRNA in lipid nanoparticles • Large clinical trial ongoing at the moment 6 Classified as public by the European Medicines Agency COVID-19 VACCINES UNDER REVIEW BY EMA Sputnik Vaccine • Start of rolling review: 04/03/2021 • Contains two different viruses belonging to the adenovirus family, Ad26 and Ad5 • These adenoviruses have been modified to contain the gene for making the SARS-CoV-2 spike protein; they cannot reproduce in the body and do not cause disease • The two adenoviruses are given separately: Ad26 is used in the first dose and Ad5 is used in the second to boost the vaccine’s effect 6 Classified as public by the European Medicines Agency Adapting COVID-19 vaccines to variants • Sars-CoV-2 variants are emerging and will continue to emerge if the virus is not stopped • This requires continuous monitoring of the vaccines’ performance over time • Regulators and developers are anticipating vaccine updates to protect against variants • This can be done reasonably quickly – based on existing knowledge with annual flu vaccines - no need for large scale trials • Studies needed to approve ‘variant vaccines’ will look at comparing immune responses between people vaccinated with the parent vaccine and people vaccinated with ‘variant vaccine’ • EMA has provided guidance to vaccine developers 7 Classified as public by the European Medicines Agency ADAPTING COVID-19 VACCINES TO VARIANTS Data from clinical trials on how COVID-19 vaccines protect from variants • Based on published studies, the vaccines authorised in the EU are expected to provide protection against the UK B.1.1.7 variant • In terms of mild disease, protection against the South African variant B.1.351 may vary depending on the vaccine; studies are needed to define extent of protection against severe disease and hospitalisation • For Brazil variant P.1 – no data available 7 Classified as public by the European Medicines Agency ADDITIONAL INFORMATION Pending questions on COVID-19 vaccines ? • Need for two doses for individuals who had a history of COVID-19 • Interval between the doses • Possibility to boost with different vaccines • Use in immunocompromised subjects and selected special population 8 Classified as public by the European Medicines Agency ADDITIONAL INFORMATION How vaccines help to beat the pandemic • Immediate benefit for people who will be protected against COVID-19 symptoms • If fewer people are getting sick (develop symptoms of COVID-19), particularly among high risk individuals such as older people, this will alleviate the huge burden of COVID-19 disease on healthcare systems • Preliminary data from Israel, with high vaccination rate and infection rates are falling, providing first evidence of vaccines reducing spread. • COVID-19 vaccines that reduce symptomatic disease will be essential to beat the pandemic • At least initially, vaccines alone will not allow us immediately to return to ‘normal’ life, and other public health measures such as face masks, hand hygiene and social distancing will remain essential 8 Classified as public by the European Medicines Agency ADDITIONAL INFORMATION Ongoing activities • 54 vaccine developers have interacted with EMA so far • ~30 vaccine companies have interacted with COVID-ETF • 42 rapid scientific advice procedures for vaccines • Guidance for developers issued on variant vaccines • Discussions ongoing for approval of additional vaccines
Load more

Recommended publications
  • 28Th WHO Regulatory Update on COVID-19
    28th WHO Regulatory Update on COVID-19 05 February 2021 Key Messages Vaccines are giving us a window of opportunity to bring the pandemic under control. The number of vaccinations globally has now overtaken the number of reported infections. But more than three quarters of those vaccinations are in just 10 countries while around 130 countries, with 2.5 billion people, are yet to start their first vaccination. WHO encourages COVID vaccine manufacturers to share their dossiers with WHO faster and more fully for assessment of emergency use listing. Highlights and main issues • WHO has been tracking virus variants since the beginning of the COVID-19 outbreak. With the emergence of new variants of concern, these efforts have been stepped-up to set up systems to quickly identify and study emerging variants. • WHO is working with relevant stakeholders on a common naming system for variants. The aim is to name variants that have potential impact on severity, on transmission and any that have any impact on diagnostics, therapeutics and vaccines. • On 3 February, COVAX has published an interim distribution forecast to provide information on early projected availability of doses of the Pfizer/BioNTech vaccine in Q1 2021 and the AstraZeneca/Oxford vaccine candidate in first half 2021 to COVAX Facility participants. • On 29 January 201, the EU granted a conditional marketing authorisation, based on a recommendation from the EMA, for the AstraZeneca COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. • The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 in people aged 18 years and older.
    [Show full text]
  • Common COVID-19 Myths and Misinformation
    Common COVID-19 Myths and Misinformation Myth: The side effects of Myth: The COVID-19 Myth: If I’ve already had the COVID-19 vaccine are vaccine can affect COVID-19, I don’t need a dangerous. women’s fertility. vaccine. Myth: Researchers rushed the development of the Myth: Getting the COVID- Myth: The COVID-19 COVID-19 vaccine, so its 19 vaccine gives you vaccine can affect effectiveness and safety COVID-19. women’s fertility. cannot be trusted. Myth: The COVID-19 vaccine enters your cells and changes your DNA. Information gathered from the following website: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccines-myth-versus-fact https://www.muhealth.org/our-stories/covid-19-vaccine-myths-vs-facts FACT: People who have gotten sick with COVID-19 may still benefit from getting vaccinated. Due to the severe health risks associated with COVID-19 and the fact that re-infection with COVID-19 is possible, people may be advised to get a COVID-19 vaccine If I’ve already had even if they have been sick with COVID-19 before. There is not enough information currently available to COVID-19, I don’t say if or for how long people are protected from getting COVID-19 after they have had it (natural need a vaccine. immunity). Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed to better understand this. Several subjects in the Pfizer trial who were previously infected got vaccinated without ill effects. Some scientists believe the vaccine offers better protection for coronavirus than natural infection.
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]
  • Covid-19 Messenger Rna Vaccine
    COVID-19 MESSENGER RNA VACCINE A Piece of the Coronavirus The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments. Image of Coronavirus and spike proteins. Spike CORONAVIRUS protein Spikes gene Like the Pfizer vaccine, Moderna’s vaccine is based on the virus’s genetic instructions for building the spike protein. mRNA Inside an Oily Shell The vaccine uses messenger RNA, genetic material that our cells read to make proteins. The molecule — called mRNA for short — is fragile and would be chopped to pieces by our natural enzymes if it were injected directly into the body. To protect their vaccine, Pfizer and BioNTech wrap mRNA in oily bubbles made of lipid nanoparticles. Lipid nanoparticles surrounding mRNA Entering a Cell After injection, the vaccine particles bump into cells and fuse to them, releasing mRNA. The cell’s molecules read its sequence and build spike proteins. The mRNA from the vaccine is eventually destroyed by the cell, leaving no permanent trace. Vaccine Particle Translating mRNA fuses into Spike Spike Protien, which beaks it into Protein fragmentsmRNA and then destroyed by the Translatingcell nucleus. mRNA Spike Three spike Proteins Combine Cell Nucleus Spike Proteins and Fragments Protruding Displaying Protein Fragments Spikes Some of the spike proteins form spikes that migrate to the surface of the cell and stick out their tips. The vaccinated cells also break up some of the proteins into fragments, which they present on their surface. These protruding spikes and spike protein fragments can then be recognized by the immune system.
    [Show full text]
  • Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
    Review Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines Carlotta Biagi 1, Arianna Dondi 1,* , Sara Scarpini 1 , Alessandro Rocca 1, Silvia Vandini 2, Giulia Poletti 1 and Marcello Lanari 1 1 Pediatric Emergency Unit, Department of Medical and Surgical Sciences (DIMEC), Sant’Orsola University Hospital, 40138 Bologna, Italy; [email protected] (C.B.); [email protected] (S.S.); [email protected] (A.R.); [email protected] (G.P.); [email protected] (M.L.) 2 Pediatric and Neonatology Unit, Imola Hospital, 40026 Imola (Bologna), Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-2144635; Fax: +39-051-2144440 Received: 14 October 2020; Accepted: 10 November 2020; Published: 11 November 2020 Abstract: Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in infants and it also induces significant disease in the elderly. The clinical course may be severe, especially in high-risk populations (infants and elderly), with a large number of deaths in developing countries and of intensive care hospitalizations worldwide. To date, prevention strategies against RSV infection is based on hygienic measures and passive immunization with humanized monoclonal antibodies, limited to selected high-risk children due to their high costs. The development of a safe and effective vaccine is a global health need and an important objective of research in this field. A growing number of RSV vaccine candidates in different formats (particle-based vaccines, vector-based vaccines, subunit vaccines and live-attenuated vaccines) are being developed and are now at different stages, many of them already being in the clinical stage.
    [Show full text]
  • Aptamer Applications in Emerging Viral Diseases
    pharmaceuticals Review Aptamer Applications in Emerging Viral Diseases Arne Krüger 1,† , Ana Paula de Jesus Santos 2,†, Vanessa de Sá 2, Henning Ulrich 2,* and Carsten Wrenger 1,* 1 Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000-SP, Brazil; [email protected] 2 Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo 05508-900-SP, Brazil; [email protected] (A.P.d.J.S.); [email protected] (V.d.S.) * Correspondence: [email protected] (H.U.); [email protected] (C.W.) † These authors contributed equally to this work. Abstract: Aptamers are single-stranded DNA or RNA molecules which are submitted to a process denominated SELEX. SELEX uses reiterative screening of a random oligonucleotide library to identify high-affinity binders to a chosen target, which may be a peptide, protein, or entire cells or viral particles. Aptamers can rival antibodies in target recognition, and benefit from their non-proteic nature, ease of modification, increased stability, and pharmacokinetic properties. This turns them into ideal candidates for diagnostic as well as therapeutic applications. Here, we review the recent accomplishments in the development of aptamers targeting emerging viral diseases, with emphasis on recent findings of aptamers binding to coronaviruses. We focus on aptamer development for diagnosis, including biosensors, in addition to aptamer modifications for stabilization in body fluids and tissue penetration. Such aptamers are aimed at in vivo diagnosis and treatment, such as quantification of viral load and blocking host cell invasion, virus assembly, or replication, respectively. Although there are currently no in vivo applications of aptamers in combating viral diseases, such Citation: Krüger, A.; de Jesus Santos, strategies are promising for therapy development in the future.
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • NOVAVAX, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) 20 Firstfield Road Delaware Gaithersburg, Maryland 20878 22-2816046 (State of incorporation) (Address of principal executive offices) (I.R.S. Employer Identification No.) Registrant’s telephone number, including area code: (240) 268-2000 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, Par Value $0.01 per share The NASDAQ Global Select Market Securities registered pursuant to Section 12(g) of the Act: Not Applicable Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Partnerships Key to Combating Viral Epidemics
    Partnerships key to combating viral epidemics Global viral threats such as Ebola and Zika have accelerated vaccine developers’ forays into public health and catalyzed new partnership strategies. feature nopparit/iStock/Thinkstock Chris Morrison In 2014, the Ebola epidemic hit West Africa, leaving governments, conducted ten trials across Africa, the United States and Europe; health organizations and biopharma companies scrambling for solu- Janssen published promising phase 1 trial results in April1. tions. As the epidemic escalated, companies partnered to advance Merck’s work in this space also highlights the key role of part- the few available vaccine candidates, none of which had reached nerships. The company evaluated the field from every angle, said clinical trials. “When there’s a public health emergency, you’re looking Gupta, before signing a deal with NewLink Genetics in November for anything,” said Swati Gupta, executive director of public health 2014. Although NewLink is better known for its portfolio of immuno- and scientific affairs for Merck Vaccines. By the time the Ebola oncology candidates, it possessed an Ebola vaccine candidate, outbreak began to ebb in 2015, at least four vaccines had entered rVSV-ZEBOV that was backed by a wealth of data from non-human first-in-human trials (Table 1). primate studies. “There were doses of vaccine already available that No sooner had the Ebola epidemic started to subside, however, were in the freezer,” said Gupta. Merck paid NewLink $30 million up than another infectious disease risk emerged. Zika virus started front, and the biotech received a $20 million milestone payment spreading through South America in 2015, and it is now threaten- when clinical trials began in early 2015.
    [Show full text]
  • Annual Report 2019 to Our Shareholders
    Annual Report 2019 To Our Shareholders Vaccines and wide-spread I want to underscore the success of NanoFlu, our vaccination practices have been adjuvanted quadrivalent influenza vaccine. Earlier this instrumental in shaping our year we announced that the Phase 3 trial of NanoFlu global community by preventing achieved all primary endpoints. With these results, we devastating diseases and saving are developing a BLA package that, when approved, will millions of lives. Recent scientific allow us to bring NanoFlu to adults over 65, increasingly and technological advances offer new potential for challenged by weakened immunity. NanoFlu addresses a vaccines to address and prevent existing and emerging serious public health threat as well as a federal mandate infectious diseases. There is no better illustration of the to find better, more effective influenza vaccines. continued need for innovative vaccines than the COVID-19 pandemic we are all confronting. In addition, we remain committed to addressing the unmet medical need for an RSV vaccine for vulnerable At Novavax, our dedication to our mission necessitates populations. Other companies have joined the effort to that we focus efforts on a vaccine that can help global defeat RSV, but our RSV-F Protein vaccines are unique health authorities address, control and potentially in demonstrating potent efficacy in late stage clinical trials eradicate SARS-CoV-2, the virus responsible for for both older adults and vaccinated pregnant mothers COVID-19. We are seeking to fulfill our mission with for the protection of their infants. The results of our trials NVX-CoV2373. give us optimism that we have viable RSV vaccines, and we will continue to work with regulatory authorities and potential partners to refine clinical trial designs with the My letter to you, the stockholders of Novavax, normally goal of bringing these life-saving vaccines to the market.
    [Show full text]
  • Covid-19 Vaccine Myths
    COVID-19 VACCINE MYTHS Family physicians want you to know what’s true. MYTH 1: You can delay routine vaccinations until the MYTH 5: The vaccine will alter my DNA. pandemic is over. This isn’t possible. mRNA vaccines work in the cell’s cytoplasm You shouldn’t postpone your vaccinations. Routine and never enter the cell nucleus, where the DNA, your genetic childhood and adult vaccinations are an important part of maintaining material, lives. It’s broken down quickly once it enters the cell and your health because they prevent other illnesses. Talk with your family delivers the needed vaccine “message” to the cell’s machinery. The physician about what vaccinations you still need and how to safely virus spike protein is also rapidly broken down once there is no longer catch up. They may have alternate times or locations to vaccinate any mRNA. The adenovirus platform uses DNA encoding the spike healthy patients, decreasing exposure to those who might be sick with protein which does enter the nucleus. However, it does not alter the COVID-19. cell’s DNA in any way. MYTH 2: The COVID-19 vaccines were developed MYTH 6: COVID-19 vaccines will deliver a microchip too fast to be safe. into my body. The technology used to develop the new mRNA There is not a microchip in the vaccines. This false rumor COVID-19 vaccines isn’t new. It’s been studied and used started after comments about digital vaccine records. State electronic for cancer research, and the original research on messenger RNA immunization records help patients and physicians track vaccines they (mRNA) vaccines is decades old.
    [Show full text]
  • A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Cell, Vol. 90, 841±847, September 5, 1997, Copyright 1997 by Cell Press A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells Teshome Mebatsion, Stefan Finke, Frank Weiland, proteins on their surface, was so far not feasible. Such and Karl-Klaus Conzelmann* an approach was until recently confined to retroviruses, Department of Clinical Virology which in the absence of their own spike protein accomo- Federal Research Center for Virus Diseases date a variety of foreign membrane proteins, such as of Animals CD4 (Young et al., 1990), to produce pseudotype vi- Paul-Ehrlich-Straûe 28 ruses. By applying a system that allows recovery of 72076 TuÈ bingen genetically altered negative strand RNA viruses from Germany cDNA (Schnell et al., 1994; reviewed in Conzelmann and Meyers, 1996), we recently found that a rhabdovirus, rabies virus (RV), is also able to form ªspikeless,º nonin- Summary fectious virus particles (Mebatsion et al., 1996a), sug- gesting the possibility of generating pseudotype viruses We show that a cellular virus receptor functions in the with an altered receptor specificity. Mammalian rhab- envelope of a virus, allowing selective infection of cells doviruses replicate in the cytoplasm of infected cells. displaying the receptor ligand. A G-deficient rabies Virus budding takes place at the cell surface where the virus (RV) pseudotyped with CD4- and CXCR4-derived viral ribonucleoprotein complex (RNP or nucleocapsid) proteins selectively infected cells expressing HIV-1 en- is enwrapped into an envelope containing an internal velope protein.
    [Show full text]